ATE443701T1 - Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion - Google Patents

Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion

Info

Publication number
ATE443701T1
ATE443701T1 AT05705638T AT05705638T ATE443701T1 AT E443701 T1 ATE443701 T1 AT E443701T1 AT 05705638 T AT05705638 T AT 05705638T AT 05705638 T AT05705638 T AT 05705638T AT E443701 T1 ATE443701 T1 AT E443701T1
Authority
AT
Austria
Prior art keywords
substituted
phenyl
lower alkyl
sulfonamidine
inhibitors
Prior art date
Application number
AT05705638T
Other languages
English (en)
Inventor
Lynn Resnick
Donna Huryn
Joan Sabalski
Joshua Berkowitz
Anthony Kreft
Dennis Kubrak
Thomas Caggiano
Koi Morris
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE443701T1 publication Critical patent/ATE443701T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT05705638T 2004-01-16 2005-01-13 Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion ATE443701T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53708604P 2004-01-16 2004-01-16
PCT/US2005/001082 WO2005073198A1 (en) 2004-01-16 2005-01-13 Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole

Publications (1)

Publication Number Publication Date
ATE443701T1 true ATE443701T1 (de) 2009-10-15

Family

ID=34825912

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05705638T ATE443701T1 (de) 2004-01-16 2005-01-13 Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion

Country Status (11)

Country Link
US (3) US7399778B2 (de)
EP (1) EP1709003B1 (de)
JP (1) JP2007517905A (de)
CN (1) CN1910158A (de)
AT (1) ATE443701T1 (de)
AU (1) AU2005207835A1 (de)
BR (1) BRPI0506765A (de)
CA (1) CA2552558A1 (de)
DE (1) DE602005016775D1 (de)
ES (1) ES2330451T3 (de)
WO (1) WO2005073198A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003237518B8 (en) * 2002-06-11 2009-03-12 Arqule, Inc. Substituted phenylsulfonamide inhibitors of beta amyloid production
AU2004230844B2 (en) 2003-03-31 2010-12-09 Wyeth Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
JP2007517905A (ja) * 2004-01-16 2007-07-05 ワイス アゾールを含有するベータアミロイド産生のヘテロ環式スルホンアミド阻害剤
MXPA06014909A (es) 2004-06-18 2007-02-28 Chiron Corp Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer.
CA2641013A1 (en) * 2006-02-17 2007-08-30 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
RU2008131051A (ru) * 2006-02-17 2010-03-27 Вайет (Us) Избирательное n-сульфонилирование 2-амино трифторалкильнзамещенных спиртов
US20090111860A1 (en) * 2006-04-21 2009-04-30 Astrazeneca Ab Sulfonamide compounds useful as adg receptor modulators
CN101472877A (zh) * 2006-04-21 2009-07-01 惠氏公司 制备手性纯氨基醇中间体、其衍生物及其用途
US7476762B2 (en) * 2006-04-21 2009-01-13 Wyeth Methods for preparing sulfonamide compounds
US7550629B2 (en) * 2006-04-21 2009-06-23 Wyeth Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
JP2010509235A (ja) * 2006-11-03 2010-03-25 ノースウェスタン ユニバーシティ 多発性硬化症の治療
WO2009012203A1 (en) * 2007-07-16 2009-01-22 Wyeth Processes and intermediates for the preparation of heterocyclic sulfonamide compounds
CL2008002060A1 (es) * 2007-07-16 2008-11-21 Wyeth Corp Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras.
PE20090824A1 (es) * 2007-07-16 2009-07-24 Wyeth Corp Proceso para la preparacion de trifluoralquil-fenil sulfonamidas y de sulfonamidas heterociclicas
TW200934482A (en) * 2008-01-11 2009-08-16 Wyeth Corp Compositions containing o-sulfate and o-phosphate containing aryl sulfonamide derivatives useful as β -amyloid inhibitors
US20110201597A1 (en) 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
EP4088717A1 (de) * 2008-03-27 2022-11-16 Chase Pharmaceuticals Corporation Kombination aus einem nspacha (peripheres anticholinergikum) wie solifenacin und einem achei (acetylcholinesteraseinhibitor) wie donepezil zur behandlung von demenz
EP2478099B1 (de) 2009-09-18 2019-06-05 Chase Pharmaceuticals Corporation Kombination zur behandlung von alzheimer-typ demenz
JP2011043839A (ja) * 2010-09-29 2011-03-03 Panasonic Corp レジスト材料及びそれを用いたパターン形成方法
CN102786447A (zh) * 2011-08-01 2012-11-21 四川大学 N,n-二取代芳基磺酰胺类化合物及其制备方法和用途
AU2013312749B2 (en) 2012-09-05 2018-01-18 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods
CN106458904B (zh) * 2014-06-10 2021-12-03 宇部兴产株式会社 N-取代磺酰胺化合物及其制造方法
US10774072B2 (en) 2014-06-10 2020-09-15 Ube Industries, Ltd. Crystal of N-substituted sulfonamide compound
EP3156395B1 (de) 2014-06-10 2019-01-09 UBE Industries, Ltd. Verfahren zur herstellung von heteroaromatischen sulfonamiden
AU2016258192B2 (en) 2015-05-06 2021-07-29 Leidos Biomedical Research, Inc. K-Ras modulators
US11358940B2 (en) 2017-04-20 2022-06-14 The Regents Of The University Of California K-Ras modulators
WO2019204505A2 (en) * 2018-04-18 2019-10-24 Theras, Inc. K-ras modulators with a vinyl sulfonamide moiety

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200209D0 (en) * 1992-01-07 1992-02-26 British Bio Technology Compounds
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
CZ184194A3 (en) 1993-08-09 1995-03-15 Lilly Co Eli Aspartylprotease inhibitor and method of identifying thereof
EP0910564B1 (de) 1995-11-28 2007-10-31 Cephalon, Inc. Aus d-aminosäuren abgeleitete cystein- und serinproteasehemmer
US5703129A (en) 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
AU5354398A (en) 1996-11-22 1998-06-10 Elan Pharmaceuticals, Inc. N-(aryl/heteroaryl) amino acid derivatives, pharmaceutical compositions compri sing same, and methods for inhibiting beta-amyloid peptide release and/or it s synthesis by use of such compounds
EP1020447A4 (de) * 1997-09-11 2000-11-15 Nissan Chemical Ind Ltd Pyrazolderivate und pflanzenschutzmittel
CN1348442A (zh) 1999-02-26 2002-05-08 默克公司 新的磺胺化合物及其应用
MXPA02001498A (es) * 1999-08-12 2003-07-21 Pharmacia & Italia S P A Derivados de 3(5)-amino-pirazol, procedimiento para la preparacion de los mismos y usos como agentes antitumorales.
EP1088815A1 (de) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutisch Aktive Sulfonyl-Aminosäurederivate
EP1088821A1 (de) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmazeutisch wirksamer Sulfonamid Derivate
EP1222176A1 (de) 1999-10-08 2002-07-17 Bristol-Myers Squibb Pharma Company Amino-laktam-sulfonamide als inhibitoren der bildung von a-beta-protein
JP2003528076A (ja) 2000-03-20 2003-09-24 メルク シャープ エンド ドーム リミテッド スルホンアミド置換架橋ビシクロアルキル誘導体
AU2001264872A1 (en) 2000-06-05 2001-12-17 Ortho-Mcneil Pharmaceutical, Inc. Method for synthesis of substituted azole libraries
US6657070B2 (en) 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
DK1341779T3 (da) 2000-12-13 2006-10-30 Wyeth Corp Heterocyklisk sulfonamid-inhibitorer af beta-amyloidproduktion
CA2470111A1 (en) 2001-12-11 2003-06-19 Wyeth Production of chirally pure .alpha.-amino acids and n-sulfonyl .alpha.-amino acids
DE10163582A1 (de) * 2001-12-21 2003-07-03 Thomson Brandt Gmbh Automatische Verstärkungsregelung für einen Tuner
AU2004230844B2 (en) * 2003-03-31 2010-12-09 Wyeth Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
JP2007517905A (ja) * 2004-01-16 2007-07-05 ワイス アゾールを含有するベータアミロイド産生のヘテロ環式スルホンアミド阻害剤

Also Published As

Publication number Publication date
US7399778B2 (en) 2008-07-15
EP1709003A1 (de) 2006-10-11
DE602005016775D1 (de) 2009-11-05
ES2330451T3 (es) 2009-12-10
US20100144812A1 (en) 2010-06-10
BRPI0506765A (pt) 2007-05-22
CA2552558A1 (en) 2005-08-11
US20050171180A1 (en) 2005-08-04
EP1709003B1 (de) 2009-09-23
AU2005207835A1 (en) 2005-08-11
US20080249150A1 (en) 2008-10-09
JP2007517905A (ja) 2007-07-05
WO2005073198A1 (en) 2005-08-11
US7674813B2 (en) 2010-03-09
CN1910158A (zh) 2007-02-07

Similar Documents

Publication Publication Date Title
DE602005016775D1 (de) Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion
MY160394A (en) Novel phenol derivative
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
CO6220935A2 (es) Derivados de 1,2,4-triazol como moduladores de mglur5
NO20081464L (no) 1-heterocyklusulfonyl, 2-aminometyl, 5-(hetero-)aryl subsidiert 1-H-pyrrol-derivater som syresekresjonsinhibitorer
PE20160540A1 (es) Inhibidores de bromodominios
PE20091952A1 (es) Compuestos de tiazole y oxazole de sulfonamida de benzeno
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
IL185844A0 (en) I-acetic acid-indole derivatives with pgd2 antagonist activity
PE20141375A1 (es) Activadores de glucoquinasa
PE20142099A1 (es) Derivados de sulfonamida
TW200738136A (en) Fungicidal N-[2-(haloalkoxy)phenyl]heteroarylcarboxamides
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
CO6140060A2 (es) Derivados de aminocicloalquil 1,2,4-triazol como moduladores de mglur5
SV2009003233A (es) Derivados de 2-(1-fenil -5- hidroxi -4alfa-metil-hexahidrociclopenta (f)indazol-5- il)etil fenilo como ligandos del receptor glucocorticoide
CL2012001171A1 (es) Procedimiento para la preparacion del ester n-[[2-[[[4-[[[(hexiloxicarbonil)]4-amino]iminometil]fenil]amino]metil]1-alquil-1h-benzimidazol-5-il]carbonil]n-2-piridinil-etilico de beta-alanina; y uno de los compuestos intermediarios considerados.
ATE453639T1 (de) Phenylsubstituierte pyrimidinverbindungen zur verwendung als kinasehemmer
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
DK1989200T3 (da) [4-(benzo[B]thiophen-2-YL)-pyrimidin-2-YL]-aminderivater som IKK-beta-inhibitorer til behandling af cancer og inflammatoriske sygdomme
PE20120655A1 (es) Derivados de triazolopiridina como inhibidores de proteinas cinasas activadas por mitogeno p38 (map)
MY150269A (en) Novel phenylpyrrole derivative
PE20120356A1 (es) Compuestos para el tratamiento de trastornos metabolicos
NZ597810A (en) Indole derivative or pharmacologically acceptable salt thereof, as ep1 receptor antagonists for the treatment of lower urinary tract dysfunction
NO20071574L (no) Arylsulfonylstilbenderivater for behandling av insomni og beslektede tilstander.
PE20090592A1 (es) Nuevos derivados de piperazina-amida

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties